177174-47-9

Usage

Uses

Used in Fragrance and Flavor Industry:
Methyl 2-methoxy-5-(trifluoromethyl)benzoate is used as a key ingredient in the production of various fragrances and flavors for its sweet, fruity odor and ability to enhance the overall scent and taste profile of products.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, methyl 2-methoxy-5-(trifluoromethyl)benzoate is utilized as an intermediate in the synthesis of various organic compounds, contributing to the development of new drugs and medicinal products.
Used in Agrochemical Industry:
Methyl 2-methoxy-5-(trifluoromethyl)benzoate is employed in the agrochemical industry for its potential applications in the development of pesticides, herbicides, and other agricultural chemicals, enhancing crop protection and yield.
Used in Organic Synthesis:
As an intermediate in organic synthesis, methyl 2-methoxy-5-(trifluoromethyl)benzoate plays a crucial role in the production of a wide range of organic compounds, facilitating advancements in various chemical and industrial applications.

Upstream product

• 2923-18-4 sodium 2,2,2-trifluoroacetate 
• 40757-09-3 methyl 2-methoxy-5-iodobenzoate 
• 22802-67-1 methyl 2-methoxy-5-aminobenzoate 
• 67-56-1 methanol 
• 4864-01-1 2-methoxy-5-(trifluoromethyl)-benzoic acid 
• 201230-82-2 carbon monoxide 
• 402-10-8 2-bromo-1-methoxy-4-(trifluoromethyl)benzene 

Downstream Products

• 79427-88-6 2-hydroxy-5-(trifluoromethyl)benzoic acid 
• 685126-89-0 (2-methoxy-5-(trifluoromethyl)phenyl)methanol 
• 933982-96-8 2-hydroxy-5-(trifluoromethyl)benzamide 

Relevant academic research and scientific papers

N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION

The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibros

Conversion of aromatic amino into trifluoromethyl groups through a Sandmeyer-type transformation

A novel strategy for aromatic trifluoromethylation by converting amino into trifluoromethyl groups via a Sandmeyer-type reaction is reported. The transformation involves diazotization of the aromatic amines with tert-butyl nitrite and hydrochloric acid to form aryldiazonium chlorides, followed by trifluoromethylation with trifluoromethylsilver at low temperature. Various readily available aromatic amines are smoothly converted under mild conditions. Georg Thieme Verlag Stuttgart. New York.

Silver-mediated trifluoromethylation of aryldiazonium salts: Conversion of amino group into trifluoromethyl group

A novel strategy for aromatic trifluoromethylation by converting aromatic amino group into CF3 group is reported herein. This method, which can be considered as trifluoromethylation variation of the classic Sandmeyer reaction, uses readily available aromatic amines as starting materials and is performed under mild conditions.

Melanocortin-4 receptor binding compounds and methods of use thereof

Provided are MC4-R binding compounds of the formula XVII: wherein L2 is a linker group, and P1, P2, P3, P4, Z1, Z2, Z3, Z4, Z5, t, s, and R are a

Synthesis and biological activity of novel 1,3-benzoxazine derivatives as K+ channel openers

A new series of 1,3-benzoxazine derivatives with a 2-pyridine 1-oxide group at C4 was designed to explore novel K+ channel openers. Synthesis was carried out by using a palladium(0)-catalyzed carbon-carbon bond formation reaction of imino-triflates with organozinc reagents and via a new one-pot 1,3-benzoxazine skeleton formation reaction of benzoylpyridines. The compounds were tested for vasorelaxant activity in tetraethylammonium chloride (TEA) and BaCl2-induced and high KCl-induced contraction of rat aorta to identify potential K+ channel openers, and also for oral hypotensive effects in spontaneously hypertensive rats. An electron- withdrawing group with the proper shape at C6 and a methyl or halogens group at C7 of the 1,3-benzoxazine nucleus were required for the development of optimal vasorelaxant and hypotensive activity. In particular, 2-(6-bromo-7- chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine 1-oxide (71) showed more potent vasorelaxant activity (EC50=0.14 μM) against TEA and BaCL2- induced contraction and longer-lasting hypotensive effects than cromakalim (1).